| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | SSTRIP; SPANK-1; synamon |
| WB Predicted band size | 225 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human SHANK1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于SHANK1抗体的代表性文献及其摘要概括：
1. **"Structural analysis of the SHANK1 N-terminal region reveals a folded domain essential for synaptic function"**
*作者：Boeckers TM et al. (2005), J Biol Chem*
摘要：解析了SHANK1蛋白N端结构域的晶体结构，并利用特异性抗体验证其在突触后密度中的定位，证明该区域对突触信号传导具有关键调控作用。
2. **"Behavioral and synaptic dysfunction in Shank1 knockout mice: Implications for autism spectrum disorders"**
*作者：Silverman JL et al. (2011), Nature Neuroscience*
摘要：通过SHANK1特异性抗体检测基因敲除小鼠模型，发现SHANK1缺失导致突触可塑性受损，并引发焦虑样行为和社交缺陷，提示其与自闭症病理相关。
3. **"SHANK1 mutations in patients with autism spectrum disorder"**
*作者：Sato D et al. (2012), Human Molecular Genetics*
摘要：利用SHANK1抗体进行蛋白表达分析，鉴定出自闭症患者中新型SHANK1错义突变，证明突变导致突触蛋白复合物组装异常。
4. **"Antibody-based profiling of synaptic proteins in neurological disorders"**
*作者：Grant SGN et al. (2005), Molecular Psychiatry*
摘要：系统评估了包括SHANK1抗体在内的多种突触蛋白检测工具，建立了标准化Western Blot和免疫组化流程用于神经疾病样本分析。
注：以上文献均为模拟案例，实际引用时请通过PubMed/Google Scholar检索真实文献(关键词：SHANK1 antibody, synaptic proteins, autism)。
SHANK1 antibodies are essential tools in neuroscience research, targeting the SHANK1 protein, a key member of the SHANK/ProSAP family of synaptic scaffolding proteins. SHANK1 is predominantly localized at the postsynaptic density (PSD) of excitatory synapses, where it organizes neurotransmitter receptors, ion channels, and signaling molecules by linking membrane proteins to the actin cytoskeleton. It plays a critical role in synaptic plasticity, neural development, and cognitive functions. Dysregulation of SHANK1 has been implicated in neurodevelopmental and psychiatric disorders, including autism spectrum disorders (ASD) and schizophrenia.
SHANK1 antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunoprecipitation to detect protein expression, localization, and interactions. These antibodies typically recognize specific domains (e.g., ANK repeats, SH3. PDZ, or proline-rich regions) or epitopes of SHANK1. with variations in clonal specificity (monoclonal vs. polyclonal) influencing experimental outcomes. Researchers often validate SHANK1 antibodies using knockout models or knockdown controls to ensure specificity, as cross-reactivity with other SHANK family members (SHANK2. SHANK3) can occur due to structural homology.
Studies leveraging SHANK1 antibodies have advanced understanding of synaptic pathology, protein networks in neurological diseases, and potential therapeutic targets. However, discrepancies in antibody performance across studies highlight the need for rigorous validation and standardized protocols.
×
